This study investigated the inhibitory effect of arctigenin, a novel anti-inflammatory lignan, on prostate cancer in obese conditions both in vitro and in vivo. In vitro obese models were established by coculture of mouse adipocytes 3T3-L1 with androgen-sensitive LNCaP human prostate cancer cells, or by culturing LNCaP cells in adipocytes-conditioned medium. Arctigenin significantly inhibited LNCaP proliferation, along with decreased androgen receptor (AR) and increased Nkx3.1 cellular expression. Male severe combined immunodeficiency mice were subcutaneously implanted with human prostate cancer LAPC-4 xenograft tumors for in vivo study. Mice were fed high-fat (HF) diet and orally given arctigenin at 50 mg/kg body weight daily or vehicle control for 6 weeks. Tumor bearing HF control mice showed a significant increase in serum free fatty acids (FFAs) and decrease in subcutaneous/peritoneal fat depots compared to non-tumor bearing control mice. Arctigenin intervention significantly reduced tumor growth by 45%, associated with decreased circulating FFAs and adipokines/cytokines including IGF-1, VEGF, and MCP-1, along with decreased AR, Ki67, and microvessel density and increased Nkx3.1 expression in tumors. These results indicate the strong ability of arctigenin to co-target obesity and tumor itself in inhibition of prostate tumor growth at a lower concentration compared to most phytochemicals.
Results
In vitro anti-proliferative effect and signaling regulation by arctigenin. Culture of LNCaP cells in obese conditions significantly enhanced cell proliferation compared to regular medium (Supp. Fig. 1 ). The anti-proliferative effect of arctigenin was assessed first in an in vitro obese model by the co-culture of LNCaP cells and 3T3-L1 adipocytes. Arctigenin treatment at 10 µM significantly inhibited LNCaP cell proliferation after 48 h incubation, with an inhibition by 50% at 96 h (Fig. 1A) . Analysis of 3T3-L1 conditioned medium revealed that the levels of three adipokines/cytokines, including IGF-1, VEGF, and MCP-1, were significantly elevated relative to blank medium (Supp. Fig. 2A ). The treatment with arctigenin significantly decreased both IGF-1 and VEGF levels in the co-culture medium as compared to control (Supp. Fig. 2B ).
The second experiment was performed using 3T3-L1 adipocytes-conditioned medium for culture of LNCaP cells. Consistent to the first experiment, the proliferation of LNCaP cells was significantly inhibited by arctigenin treatment in a time-and dose-dependent manner (Fig. 1B) . Western blot analysis showed that the protein expression of AR in LNCaP cells was significantly reduced by arctigenin after 24 h treatment (Fig. 1C ), along with an increased protein expression of Nkx3.1 at 48 h ( Fig. 1D) . RT-PCR analysis demonstrated a significant increase in Nkx3.1 mRNA expression at 24 h of arctigenin treatment (Fig. 1E ).
Tumor growth inhibition and blood/tumor concentrations of arctigenin. To investigate the effect of different diets on tumor growth, mice of xenograft prostate tumors were fed either high-fat (HF) diet or regular low-fat (LF) diet for 6 weeks. The consumption of HF diet significantly increased tumor growth as compared to LF diet ( Fig. 2A ). Arctigenin intervention in mice on HF diet slowed down tumor growth as compared to HF control ( Fig. 2A ). Tumor growth was significantly inhibited by 45% after 5-weeks arctigenin intervention compared to HF control ( Fig. 2A) . Tumor weight at sacrifice showed consistent pattern with that of tumor volume ( Fig. 2B ).
Arctigenin was undetectable in the HF control group, while detectable in all the blood and tumor samples from the HF arctigenin group. The blood concentration of arctigenin was 0.65 ± 0.49 µmol/L, and tumor concentration 0.70 ± 0.39 nmol/g tumor ( Fig. 2C) , with a significant correlation between blood and tumor concentrations (r = 0.98, P < 0.01).
Reduced tumor proliferation marker and microvessel density. Immunohistochemical analysis of
tumor tissues showed that the proliferation marker nuclear Ki67 protein levels were significantly reduced by 50% in arctigenin group compared to HF control (Fig. 3A ). In addition, regarding the important role of angiogenesis in tumor development and progression, we evaluated the anti-angiogenic ability of arctigenin in this study. CD31, also known as platelet endothelial cell adhesion molecule-1 (PECAM-1), is a membrane glycoprotein highly expressed in early and mature endothelial cells, and commonly used as a staining marker for microvessels in evaluation of tumor angiogenesis 25, 26 . A strong inhibition of tumor angiogenesis was observed with arctigenin treatment, as indicated by a 70% reduction of total microvessel density, as well as the density of microvessels with lumen, in tumor tissues of arctigenin group as compared to HF control ( Fig. 3B ).
Modulation of signaling molecules. Western blot analysis of important signaling molecules involved in
prostate cancer demonstrated that the AR protein expression was significantly reduced by arctigenin treatment compared to HF control, along with a significantly increased protein expression of Nkx3.1 (Fig. 4A,B) . The blood concentrations of several major obesity-related adipokines/cytokines were significantly elevated in HF control mice compared to that in LF control ( Fig. 4C ). Arctigenin treatment significantly decreased the blood levels of leptin, tumor necrosis factor (TNF)-α, IGF-1, interleukin (IL)-6, VEGF, IL-1a, IL-1b, and MCP-1 by 30-35% compared to HF control ( Fig. 4C ).
Metabolic regulations by arctigenin.
There was no significant difference in mouse body weight between the arctigenin and control groups on HF diet ( Fig. 5A ). However, as compared to the non-tumor control mice that were fed high-fat diet (HF Non-tumor Con), mice bearing tumors had significantly reduced body weights after 4 weeks of tumor cell inoculation (Fig. 5A ). Body weights in HF arctigenin group were comparable to that of LF non-tumor bearing mice, while body weights of HF control mice showed a slight trend while not statistically significant decrease starting 3 weeks post tumor inoculation ( Fig. 5A ). The weight of white adipose tissue (WAT), particularly the subcutaneous WAT, was proportional to mouse body weight (r = 0.62, P < 0.05), with a significantly reduced level in the tumor-bearing HF control mice compared to other groups (Fig. 5B ). There was no difference in brown adipose tissue weight among groups (Fig. 5B ). Consistent with our observation of reduced subcutaneous WAT mass in HF control mice, there was a significant reduction in adipocyte size of the subcutaneous WAT in HF control group compared to other groups (Fig. 5C ).
Blood FFA, which is mainly released from adipose tissue, is an important source of fatty acid for tumor cell proliferation in vivo 27 . In this study we found that serum FFA levels were significantly higher in the tumor-bearing HF control mice compared to non-tumor mice and arctigenin-treated HF mice ( Fig. 5D ). There was no difference in blood triglyceride levels between HF arctigenin and HF control groups, while both groups had lower blood triglyceride levels as compared to HF non-tumor mice ( Fig. 5E ). There was no difference in blood cholesterol levels among the four groups (data not shown). The blood glucose levels in HF control mice were significantly lower as compared to non-tumor control mice, while the levels in HF arctigenin-treated mice were comparable to that in Figure 2 . Arctigenin inhibits xenograft prostate tumor growth in high-fat diet fed SCID mice. Male SCID mice were fed either a high-fat (HF) diet or a regular low-fat (LF) diet (n = 10 per group). One week later, mice were inoculated subcutaneously with 5 × 10 5 androgen-sensitive human prostate cancer LAPC-4 cells. The intervention started one week post tumor cell inoculation when tumors reached a volume of around 10 mm 3 . Mice were treated with either arctigenin at 50 mg/kg or vehicle control. Tumor size was measured once a week using calipers and tumor volume (A) calculated using the formula: length × width × height × 0.5236. Tumor weight (B) was measured at mouse sacrifice. Arctigenin was detected in blood and tumor from arctigenin supplemented mice (C) with HPLC coupled with CoulArray electrochemical detector after extraction with ethyl acetate. Data are presented as mean ± SD. Con: vehicle control; Arc: arctigenin. *Compared to control, P < 0.05.
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www.nature.com/scientificreports www.nature.com/scientificreports/ non-tumor mice ( Fig. 5F ). The blood insulin levels were higher in HF non-tumor mice compared to other groups, while there was no difference between HF arctigenin and HF control groups (Fig. 5G ).
Discussion
We demonstrate in this study that arctigenin, at relatively low doses, significantly inhibited prostate cancer growth in obese conditions both in vitro and in vivo. Obesity elevates circulating levels of multiple growth factors and pro-inflammatory cytokines/chemokines, such as IGF-1, VEGF and MCP-1 among others, leading to accelerated tumor growth as demonstrated in this study and by other investigators 5, 28 . In addition, obesity contributes to the failure of cancer treatments due to increased inflammation, metabolic perturbation, and induction of chemoresistance 8 . Therefore, it is critical to co-target obesity in prevention and treatment of cancer particularly in obese patients. We previously demonstrated a strong anti-tumor effect of arctigenin in the non-obese state with an IC 50 value of 2 µM in LNCaP cells, which is about 10-20 fold stronger than most of phytochemicals being studied including green tea polyphenols 15, 29 . The culture of LNCaP cells with adipocytes or with adipocytes-conditioned medium in the present study moderately increased the IC 50 of arctigenin to 5-10 µM, at least partly due to the adipocytes' secretion of multiple growth factors such as IGF-1, VEGF and MCP-1 into the co-culture medium. Our in vivo study further confirmed the anti-tumor effect of arctigenin in obese conditions by showing a 45% inhibition of prostate tumor growth, along with significantly reduced tumor expression of the proliferation marker Ki67. The in vivo anti-tumor potency of arctigenin as demonstrated in this study was close to our previous observations in LF diet fed SCID mice where arctigenin inhibited xenograft prostate tumor growth by 50% at the same dose level (equivalent to 300 mg arctigenin daily for an average adult) 15 . These results support arctigenin to be a strong anticancer agent in both non-obese and obese states. The blood concentration of arctigenin in this study was similar to that we observed previously in the LF diet fed mice (0.62 ± 0.07 μmol/L), while the tumor concentration of arctigenin in this study was lower than that in the LF diet fed mice (4.7 ± 3.3 nmol/g) in our previous study 15 , which may suggest a reduced cellular uptake of arctigenin in the relatively nutrient (fatty acids)-rich environment in this study.
Our mechanistic investigations revealed that the reduced tumor growth by arctigenin treatment was associated with a reduction of microvessel density in tumors. Angiogenesis is critically important for the growth of solid tumors, and tumors will remain in dormant phase for a long time in absence of blood vessel formation 20,21 . www.nature.com/scientificreports www.nature.com/scientificreports/ The anti-angiogenic activity of arctigenin was also observed in previous studies associated with the inhibition of tumor growth and invasion 30, 31 . Tumor angiogenesis is significantly enhanced in obese state, mainly due to the elevated circulating pro-angiogenic/-inflammatory factors released from adipocytes, such as VEGF, IGF-1, MCP-1, IL-1, TNF, etc 24 . Results from this study demonstrate the ability of arctigenin to regulate the expression of these pro-angiogenic/-inflammatory factors, leading to a strong inhibition of tumor angiogenesis in the studied stimulatory environment. The ability of arctigenin to metabolically regulate supplies of cancer nutrients such as fatty acids as demonstrated in this study may contribute to its anti-tumor effect. Fatty acids are essential for cancer cell proliferation by providing building blocks for synthesis of membranes and signaling molecules as well as supply of energy 32 . Circulating free fatty acids released from adipocytes are the major supply of fatty acids to tumor cells, and limiting the availability of fatty acids to cancer cells have shown to be effective in inhibition of proliferation of different cancer cells 32, 33 . In the present study, we observed that blood concentrations of free fatty acids in HF control mice were even higher than that in HF non-tumor mice, which is opposite to their body weights or adipose tissue weights. This suggests that cancer cells may be able to induce the release of free fatty acid from adipocytes to satisfy their growth need, and this may eventually lead to a state of cachexia as a sign of which in this study was a decreasing trend in body weights of HF control mice after three weeks of tumor growth. Elevated blood free fatty acid as a result of elevated lipolysis due to increased energy expenditure was also observed in previous studies at early stage of cancer cachexia 34, 35 . A decrease in blood glucose level due to tumor presence was also reported in previous studies, associated with loss in body weight and fat weight as a result of increased energy expenditure by tumor growth 36, 37 . However, blood glucose levels were still within normal values in many patients of cachexia, although blood insulin levels could be high, normal or low in correlation with degree of weight loss 38 . Blood triglycerides mainly come from dietary intake, and previous studies found that blood triglyceride levels were irrespective of the extent of weight loss in cancer cachexia 39 . In our study the mice were fed high-fat diet and the food consumption was similar in HF control and HF Arc groups, which may explain the similarity of blood triglyceride levels observed between these two groups. Arctigenin was able to significantly reduce the circulating free fatty acid levels compare to HF control, and to maintain mouse body weight and blood free fatty acid and glucose at levels comparable to that in LF non-tumor mice. These data suggest the strength of arctigenin in regulation of the systemic environment to control external tumor-promoting factors in inhibition of tumor growth.
The direct regulation of tumor cell signaling is involved in the mechanisms of arctigenin in tumor inhibition. We previously found that arctigenin is a strong inhibitor of the AR signaling in non-obese state both in vitro and in vivo, while it is a stimulator of the Nkx3.1 signaling in prostate tumor cells 15, 40 . The present study further demonstrates the association of AR and Nkx3.1 with the tumor inhibitory effect of arctigenin in obese conditions. AR is a key modulator of proliferation and progression of prostate cancer, which makes it an important target in prostate cancer chemoprevention and treatment 41 . AR has also been found to be positively associated with VEGF levels in human prostate tumors 42 , partly through the activation of hypoxia-inducible factor 1 (HIF-1) 43 . Therefore the reduced angiogenesis in the present study may be partly due to the suppressed AR expression by arctigenin treatment. Nkx3.1 is found to be a prostate tumor suppressor, and loss of Nkx3.1 protein expression is commonly observed in prostate tumors 19 . The increased Nkx3.1 expression under arctigenin treatment in this study was concurrent with the decrease in AR expression, and may contribute to the tumor-inhibitory effect of arctigenin. These data support the strong capacity of arctigenin in regulating multiple aberrant tumor signaling pathways in control of tumor growth.
In summary, this study demonstrates the strength of arctigenin in inhibition of prostate cancer growth both in vitro and in vivo in obese conditions. The anti-tumor effect of arctigenin was associated with its dual actions on both tumor itself to control dysregulated tumor signaling like AR and Nkx3.1 and on adipose tissues to reduce the secretion of pro-cancer adipokines/cytokines as well as the release of free fatty acid. Considering the challenge greatly increased by obesity in treatment of cancers, this study is anticipated to bring significant benefits in treatment of prostate cancer particularly in obese patients by providing a promising agent to co-target obesity and cancer in a non-toxic manner.
Methods
Cell culture and adipocyte differentiation. Androgen-sensitive LNCaP and LAPC-4 human prostate cancer cell lines were purchased from ATCC (Chicago, IL, USA), maintained in RPMI 1640 medium supplemented with 10% (v:v) of fetal bovine serum (FBS), 100 IU/mL of penicillin and 100 µg/mL of streptomycin at 37 °C in a 5% CO 2 incubator. 3T3-L1 mouse embryonic fibroblasts (ATCC) were cultured in Dulbecco's modified Eagle's medium supplanted with 10% FBS, 100 IU/mL of penicillin and 100 µg/mL of streptomycin. Differentiation of 3T3-L1 into adipocytes was performed as described previously with minor modifications 44 . Briefly, 3T3-L1 cells were grown into confluence and incubated as confluent culture for another 48 h. Cells were then treated with differentiation medium composed of growth medium plus 1.0 μM dexamethasone, 0.5 mM methylisobutylxanthine, and 1.0 μg/mL Insulin (all from Sigma-Aldrich, St. Louis, MO). Cells were incubated for 12 days in differentiation medium with fresh medium replaced every 48 h. The full differentiation was evidenced by observation of lipid droplet formation by light microscopy, and the differentiated adipocytes were maintained in growth medium. All cell lines were tested periodically for mycoplasma contamination. Passages of cell lines less than 10 were used for this study.
In vitro cell proliferation assay. In the first experiment, an in vitro obesity model was constructed by co-culturing of LNCaP cells and 3T3-L1 adipocytes in a 24-well plate. Adipocytes were seeded on the bottom of wells at a density of 80 cells per µL in 600 µL RPMI medium 24 h prior to LNCaP seeding on inserts. Adipocytes-conditioned medium was collected on the day of LNCaP seeding and mixed with fresh RPMI medium at 3:7 ratio (v:v) as co-culture medium. LNCaP cells were seeded at 80 cells/uL on the Falcon Cell Culture Inserts with a pore size of 0.4 μM (Fisher Scientific). Arctigenin treatment at 10 µM or DMSO control was added to the co-culture medium. Fresh co-culture medium plus treatments was replaced at 48 h for the 96 h time point. To detect cell proliferation, the inserts with LNCaP cells were transferred to a clean 24-well plate and adenosine triphosphate (ATP) assay reagent from the CellTiter-Glo Luminescent cell viability assay kit (Promega Corporation, Madison, WI) was added to each insert following the manufacturer's instruction. After incubation, 200 uL of supernatant was transferred to an opaque wall 96-well plates for chemiluminescence detection.
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Animal study. All procedures carried out in mice were approved by the Institutional Animal Care and Use Committee at Charles R. Drew University of Medicine and Science (protocol # I-1606-277). All methods were performed in accordance with the relevant guidelines and regulations. Male severe combined immunodeficiency (SCID) mice at age of 5-7 weeks (Charles River Laboratories) were acclimatized on sterilized AIN-93G diet (Dyets Inc., Bethlehem, PA) and water for one week. Mice were then fed a HF diet containing 45% energy from fat (Research Diets, Inc., New Brunswick, NJ) until the end of the study. One week after the start of HF diet, mice were inoculated subcutaneously with 5 × 10 5 androgen-sensitive LAPC-4 human prostate cancer cells. The intervention started one week later when tumors reached a volume of around 10 mm 3 . Mice were randomly assigned to receive arctigenin at 50 mg/kg body weight (b.w.) daily or vehicle control (2% DMSO in corn oil) through oral gavage, with 10 mice in each group. An additional control group (n = 10) fed regular LF diet containing 10% energy from fat (Research Diets) was added in parallel for comparison of the diet effect on tumor growth. Tumor size was measured once a week using calipers. Tumor volume was calculated with the formula: length × width × height × 0.5236 45 . Mouse body weight was measured once a week. The intervention lasted for 6-weeks. In addition, two groups of SCID mice without tumor inoculation were included on either HF diet or LF diet (n = 10 per group) for comparison of metabolic parameters and body weights.
Western blot analysis of protein marker expression.
In the in vitro study, LNCaP cells were cultured in medium containing 3T3-L1 adipocytes-conditioned medium plus fresh RPMI medium at 1:1 ratio, and treated with 5 µM of arctigenin or DMSO control for 6 h, 24 h, and 48 h. Total protein was extracted from the cells for Western blot analysis of AR and Nkx3.1 expression following procedures as described previously 46, 47 . Three biologically independent experiments were performed, and each protein sample was detected in duplicate in Western blot analysis. Mean values and standard deviations were calculated from the total 6 values of each sample. Total protein extracted from tumor tissues of the mouse studies (n = 10 mice per group, each sample tested in duplicate) was also measured for AR and Nkx3.1 expression. Membranes were incubated with primary antibody for detection of AR (sc-7305) or Nkx3.1 (sc-15022, Santa Cruz, CA). GAPDH protein was used as loading control.
Quantitative real-time PCR analysis of Nkx3.1 gene expression.
LNCaP cells were treated the same as above for western blot analysis. Total RNA was extracted for quantitative real-time PCR analysis following previous procedures 47, 48 . The final volume of the 20 μL real-time PCR mixture contained 5 μL of cDNA template, 1 μL of each primer, 10 μL of SYBR Green (Qiagen, Valencia, CA), and 3 μL of nuclease-free water. Each sample was measured in triplicate. The 2 −(∆∆Ct) method was used to normalize the expression of Nkx3.1 to GAPDH and to compare the average ∆Ct value. The primers for Nkx3.1 included the forward 5′-GAA TCC GTA TGC CCC GCT GAA TCT-3′ and reverse 5′-ACC CTT GCC AGT GCG TGT GC-3′. Primers for GAPDH include the forward 5′-CAT GTT CGT CAT GGG TGT GA-3′ and reverse 5′-GGT GCT AAG CAG TTG GTG GT-3′. Three biologically independent experiments were performed, and each sample was measured in triplicate in PCR analysis.
HPLC detection of arctigenin in mouse blood and tumor tissues. Blood (n = 10 in each group) and tumor (n = 10 in each group) samples collected from mice on HF diet, including the control and arctigenin groups, were measured for arctigenin concentrations following a previous method 15, 46 . Briefly, 200 µl of serum was extracted twice with 1 mL of ethyl acetate each time. For tumors, about 150 mg of tumor tissue was homogenized in 200 µl of water containing 2% ascorbic acid, and extracted twice with 1 mL of ethyl acetate each time. The supernatant was pooled, dried under nitrogen flow and reconstituted for high-performance liquid chromatography (HPLC) detection coupled with a CoulArray electrochemical detector (ThermoFisher Scientific, Madison WI).
Immunohistochemical analysis of tumor Ki67 expression and microvessel density.
A section of each tumor (n = 10 in each group) from mice on HF diet, including the control and arctigenin groups, was fixed in 10% phosphate buffered formalin and paraffin-embedded for tissue microarray and immunohistochemical detection as described previously 49 . The tissue array was assembled with 6 cylindrical cores from each tumor. Slides were incubated with monoclonal anti-human Ki67 or anti-mouse CD31 antibody for microvessel (DAKO North America Inc., Carpineteria, CA), and counterstained with hematoxylin. Slides were scanned on a ScanScope AT (Aperio Technologies, Inc., Vista, CA) and morphometric analysis performed digitally with Definiens' Tissue Studio (Definiens Inc., Parsippany, NJ) in a non-biased method. Briefly, the nuclear detection module and classification tool were pre-defined to identify positive and negative nuclei within each core. Thresholds were set to classify negative nuclei with hematoxylin stain and positive nuclei with DAB stain. Data were exported to Excel for statistical analysis. Scanning and analyses were performed at the UCLA Department of Pathology.
Measurement of obesity-related growth factors.
The concentrations of 8 obesity-related growth factors in cell culture medium (three biologically independent experiments, each samples tested in duplicate) or in mouse blood (n = 10 in each group, each samples tested in duplicate) were measured using a Mouse Obesity ELISA Strip kit (Signosis, inc., Santa Clara, CA) following the manufacturer's instruction. Briefly, 100 µL of cell culture medium or 100 µL of 1:10 diluted blood was loaded on the 8-well strip pre-coated with different
